EC
KLRS

EcoR1 Capital’s Kalaris Therapeutics KLRS Stock Holding History

EcoR1 Capital’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-201,718
Closed -$1.62M – 52
2025
Q1 		$1.62M Buy
201,718
+183,949
+1,035% +$1.8M 0.1% 38
2024
Q4 		$3.95M Sell
17,769
-473,300
-96% -$7.16M 0.15% 46
2024
Q3 		$9.13M Hold
491,069
– – 0.31% 43
2024
Q2 		$8.17M Hold
491,069
– – 0.25% 43
2024
Q1 		$8.53M Buy
+491,069
New +$8.01M 0.22% 45
2021
Q3 		– Sell
-19,435
Closed -$8.82M – 77
2021
Q2 		$8.82M Hold
19,435
– – 0.33% 37
2021
Q1 		$10.5M Hold
19,435
– – 0.46% 30
2020
Q4 		$17.2M Hold
19,435
– – 0.92% 23
2020
Q3 		$12.3M Buy
+19,435
New +$13.3M 0.88% 22

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EcoR1 Capital's KLRS Position: Q2 2025 in Review

EcoR1 Capital sold out of Kalaris Therapeutics (KLRS) in Q2 2025, closing a stake of 201,718 shares — an estimated $1.62M sold.

EcoR1 Capital first reported a position in KLRS in Q3 2020 and held it in 9 quarters. The position peaked at $17.2M in Q4 2020. 30 funds tracked by Wall St. Rank hold KLRS as of Q2 2025.

  • EcoR1 Capital reported no remaining Kalaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EcoR1 Capital sold 201,718 Kalaris Therapeutics shares in Q2 2025, an estimated $1.62M.
  • EcoR1 Capital first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 9 quarters.
  • EcoR1 Capital's Kalaris Therapeutics position peaked at $17.2M in Q4 2020.
  • 30 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2025.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.